EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Between research and introduction to clinical routine—Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis)

Jacek P Grabowski, Julia Welz, Sabine Heublein, Maja Krajewska, Jolijn D Boer, Fabian Kraus, Tjadina Arndt, Nicolas Moosmann, Bernhard Heinrich, Tobias Engler, Saida Agabejli, Mustafa Celalettin Ugur und 8 weitere

Archives of Gynecology and Obstetrics · 06.01.2026 · 313 (1)

DOI: 10.1007/s00404-025-08295-x ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 06.01.2026. Verfasst von Jacek P Grabowski und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany. jacek.grabowski@charite.de. Hauptthemen laut MEDLINE: Indazoles, Ovarian Neoplasms, Piperidines, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK Research & Development Limited, Charité - Universitätsmedizin Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Ovarian cancer (OC) is frequently diagnosed at a late, advanced stage, resulting in poor survival outcomes. PARP inhibitors like niraparib have shown significant efficacy in high-grade OC, particularly in tumors with homologous recombination deficiency, including BRCA mutations. This study aimed to evaluate dose modifications, safety, tolerability, and the impact on quality of life associated with niraparib in real-world clinical practice.

Methods

This non-interventional, register-based study included patients with platinum-sensitive recurrent OC who received niraparib as part of the compassionate-use program (CUP) in Germany. Clinical baseline characteristics, treatment data, adverse events (AEs), and quality-of-life measures were collected both prospectively and retrospectively across 14 centers. Data analysis was performed using descriptive statistical methods.

Results

Overall, 68 female patients were enrolled in the CUP register. Most patients had good performance status, with no significant comorbidities or concomitant medications. The most frequently reported AEs associated with niraparib were thrombocytopenia, fatigue, and nausea. Approximately half of patients required dose adjustments. AEs were less common in patients with normal physical examination findings, better ECOG performance status, and absence of comorbidities. Prior use of PARP inhibitors or previous treatment-related side effects increased the likelihood of AEs during niraparib therapy. The median treatment duration was 182 days, with disease progression being the most common reason for discontinuation.

Conclusion

Niraparib treatment within the German CUP demonstrated favorable safety and tolerability profiles, supporting its effectiveness in a real-world setting for patients with recurrent OC. These findings are consistent with results from clinical trials, further reinforcing the role of niraparib in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IndazolesOvarian NeoplasmsPiperidinesPoly(ADP-ribose) Polymerase InhibitorsAdultAgedFemaleHumansMiddle AgedCompassionate Use TrialsGermanyProspective StudiesQuality of LifeRegistriesRetrospective Studies

Stichwörter der Autor:innen

CUPClinical experienceOvarian cancerPARP-InhibitorReal-world

Substanzen

IndazolesniraparibPiperidinesPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, Berlin, Germany. jacek.grabowski@charite.de.
  • Nord-Ostdeutsche Gesellschaft Für Gynäkologische Onkologie, Berlin, Germany. jacek.grabowski@charite.de.
  • Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany.
  • Department of Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany.
  • Department of Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany.
  • Institute of Biometry and Clinical Epidemiology, Charité University Medicine of Berlin-Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.

Förderung

  • GSK Research & Development Limited
  • Charité - Universitätsmedizin Berlin

Zitieren

APA

Grabowski, J. P., Welz, J., Heublein, S., Krajewska, M., Boer, J. D., Kraus, F., Arndt, T., Moosmann, N., Heinrich, B., Engler, T., Agabejli, S., Ugur, M. C., Witteler, R., Albrecht, O., Müller-Huesmann, H., Oskay-Özcelik, G., Hettwer, C., Kaiser, S., Braicu, E., & Sehouli, J. (2026). Between research and introduction to clinical routine—Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis). Archives of Gynecology and Obstetrics, 313(1). https://doi.org/10.1007/s00404-025-08295-x

Vancouver

Grabowski JP, Welz J, Heublein S, Krajewska M, Boer JD, Kraus F, et al. Between research and introduction to clinical routine—Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis). Archives of Gynecology and Obstetrics. 2026;313(1). doi:10.1007/s00404-025-08295-x

BibTeX
@article{Grabowski2026,
  author = {Grabowski, Jacek P and Welz, Julia and Heublein, Sabine and Krajewska, Maja and Boer, Jolijn D and Kraus, Fabian and Arndt, Tjadina and Moosmann, Nicolas and Heinrich, Bernhard and Engler, Tobias and Agabejli, Saida and Ugur, Mustafa Celalettin and Witteler, Ralf and Albrecht, Oliver and Müller-Huesmann, Harald and Oskay-Özcelik, Gülten and Hettwer, Cristina and Kaiser, Sabrina and Braicu, Elena and Sehouli, Jalid},
  title = {Between research and introduction to clinical routine—Experience with niraparib from the compassionate use program in Germany (NOGGO Register Analysis)},
  journal = {Archives of Gynecology and Obstetrics},
  year = {2026},
  volume = {313},
  number = {1},
  doi = {10.1007/s00404-025-08295-x}
}
Kostenlos starten →